Should Biosimilars Be Cheap? Sponsors Aren't So Sure
Executive Summary
Policymakers often frame the value of biosimilars in terms of how inexpensive they are, but sponsors use arguments that resemble those of their innovator counterparts.
You may also be interested in...
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.